ONX-0801
id:
onx-0801-309-2431711
title:
ONX-0801
text:
ONX-0801 is an experimental drug that has been developed to target ovarian cancer. It is a folate receptor alpha mediated thymidylate synthase inhibitor. ONX-0801 was originally developed by BTG and the Institute of Cancer Research in the UK, and subsequently licensed to Onyx Pharmaceuticals for clinical development. It is designed to selectively target tumour tissues of certain kinds of cancer. It is poorly absorbed into most cells, but is actively transported by folate receptor alpha (FRα), wh
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/ONX-0801
date created:
date modified:
2023-04-05T23:37:28Z
main entity:
{"identifier":"Q27452165","url":"https://www.wikidata.org/entity/Q27452165"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/3/37/ONX-0801_structure.png","width":920,"height":496}
fields total:
13
integrity:
15